{"title":"Systems pharmacology of phytochemical anacardic acid in the chemoprevention of hepatocellular carcinoma.","authors":"Sangita Panda, Enketeswara Subudhi, Sweta Padma Routray, Sujit Nair","doi":"10.1515/dmpt-2024-0099","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Hepatocellular carcinoma (HCC) is a common type of liver cancer that progresses quickly and has limited treatment options. Nutraceutical anacardic acid (AA), a bioactive compound derived from cashew nut shell, has emerged as a potential candidate for HCC treatment owing to its reported anti-inflammatory, anticancer and diverse pharmacological properties. In the present study, we investigate the potential of AA as an HCC inhibitor using molecular docking, gene ontology, and network pharmacology.</p><p><strong>Methods: </strong>The pharmacokinetic and physicochemical properties of AA were assessed using Swiss ADME. SuperPred, Similarity Ensemble Approach, ChEMBL and Swiss Target Prediction online tools were used for determining molecular targets of AA. In addition, GeneCards, NCBI, DisGeNET and UniProt ID were used to search the targets of HCC and the top 25 hub genes were determined using Cytohubba plugin. A protein protein interaction (PPI) network was constructed through the STRING database. Gene Ontology (GO) biological process and Kyoto Encyclopaedia of Genes and Genes (KEGG) pathway enrichment analysis were performed through FunRich and ShinyGO 0.77. Moreover, molecular docking studies were performed on NF-κB and GSK-3β. The expression levels of the hub genes were also validated by western blotting.</p><p><strong>Results: </strong>Comprehensive data analysis identified 375 targets for AA and 11,333 for HCC, with 264 targets in common. Network analysis determined 25 key HCC targets, including caspase-3, and NF-κB. Gene ontology and topology analysis highlighted essential pathways implicated in HCC progression such as the renin-angiotensin system, VEGF signalling, and apoptosis. Molecular docking analysis revealed strong binding affinity of HCC proteins with NF-κB and GSK-3β. Upregulation of p-NRF2 and p-GSK-3β, and downregulation of p-NF-κB and caspase-1 expression were validated using western blotting.</p><p><strong>Conclusions: </strong>Taken together, our study highlights the potential of AA as a promising chemopreventive agent for HCC because of its significant modulatory effects on important regulatory proteins linked to cell division, inflammation, apoptosis, and antioxidant response.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug metabolism and personalized therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/dmpt-2024-0099","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Hepatocellular carcinoma (HCC) is a common type of liver cancer that progresses quickly and has limited treatment options. Nutraceutical anacardic acid (AA), a bioactive compound derived from cashew nut shell, has emerged as a potential candidate for HCC treatment owing to its reported anti-inflammatory, anticancer and diverse pharmacological properties. In the present study, we investigate the potential of AA as an HCC inhibitor using molecular docking, gene ontology, and network pharmacology.
Methods: The pharmacokinetic and physicochemical properties of AA were assessed using Swiss ADME. SuperPred, Similarity Ensemble Approach, ChEMBL and Swiss Target Prediction online tools were used for determining molecular targets of AA. In addition, GeneCards, NCBI, DisGeNET and UniProt ID were used to search the targets of HCC and the top 25 hub genes were determined using Cytohubba plugin. A protein protein interaction (PPI) network was constructed through the STRING database. Gene Ontology (GO) biological process and Kyoto Encyclopaedia of Genes and Genes (KEGG) pathway enrichment analysis were performed through FunRich and ShinyGO 0.77. Moreover, molecular docking studies were performed on NF-κB and GSK-3β. The expression levels of the hub genes were also validated by western blotting.
Results: Comprehensive data analysis identified 375 targets for AA and 11,333 for HCC, with 264 targets in common. Network analysis determined 25 key HCC targets, including caspase-3, and NF-κB. Gene ontology and topology analysis highlighted essential pathways implicated in HCC progression such as the renin-angiotensin system, VEGF signalling, and apoptosis. Molecular docking analysis revealed strong binding affinity of HCC proteins with NF-κB and GSK-3β. Upregulation of p-NRF2 and p-GSK-3β, and downregulation of p-NF-κB and caspase-1 expression were validated using western blotting.
Conclusions: Taken together, our study highlights the potential of AA as a promising chemopreventive agent for HCC because of its significant modulatory effects on important regulatory proteins linked to cell division, inflammation, apoptosis, and antioxidant response.
期刊介绍:
Drug Metabolism and Personalized Therapy (DMPT) is a peer-reviewed journal, and is abstracted/indexed in relevant major Abstracting Services. It provides up-to-date research articles, reviews and opinion papers in the wide field of drug metabolism research, covering established, new and potential drugs, environmentally toxic chemicals, the mechanisms by which drugs may interact with each other and with biological systems, and the pharmacological and toxicological consequences of these interactions and drug metabolism and excretion. Topics: drug metabolizing enzymes, pharmacogenetics and pharmacogenomics, biochemical pharmacology, molecular pathology, clinical pharmacology, pharmacokinetics and drug-drug interactions, immunopharmacology, neuropsychopharmacology.